Format

Send to

Choose Destination
JCI Insight. 2018 Jul 12;3(13). pii: 96836. doi: 10.1172/jci.insight.96836.

Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

Author information

1
Department of Cardiothoracic Surgery.
2
Department of Cell and Developmental Biology, and.
3
Neuberger Berman Lung Cancer Center, Weill Cornell Medicine, New York, New York, USA.
4
Weill Cornell Graduate School of Medical Sciences, New York, New York, USA.
5
Department of Pathology, Weill Cornell Medicine, New York, New York, USA.
6
Caryl and Israel Englander Institute for Precision Medicine, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA.
7
Houston Methodist Research Institute, Houston, Texas, USA.

Abstract

Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated analysis of early-stage NSCLC patients and a Kras mutant mouse model, we show a prevalent programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis exemplified by increased intratumoral PD-1+ T cells and PD-L1 expression. Notably, tumor progression was associated with spatiotemporal modulation of the immune microenvironment with dominant immunosuppressive phenotypes at later phases of tumor growth. Importantly, PD-1 inhibition controlled tumor growth, improved overall survival, and reprogrammed tumor-associated lymphoid and myeloid cells. Depletion of T lymphocyte subsets demonstrated synergistic effects of those populations on PD-1 inhibition of tumor growth. Transcriptome analyses revealed T cell subset-specific alterations corresponding to degree of response to the treatment. These results provide insights into temporal evolution of the phenotypic effects of PD-1/PD-L1 activation and inhibition and motivate targeting of this axis early in lung cancer progression.

KEYWORDS:

Cancer immunotherapy; Immunology; Lung cancer; Oncology; T cells

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center